Page 167 - Genomic Medicine in Emerging Economies

156 CHAPTER 8: E c o n omic Evaluation and Cost-Effectiveness Analysis

In essence, conducting basic research to discover important advances in the
applications of genetics, as well as economic analysis to determine the finan-
cial consequences of these adoptions, is important in order to ensure that
patients receive an acceptable level of care while effectively managing health
care resources. As the benefits of genetics have been partially acknowledged by
general practitioners, but also remain under consideration, similar scientific
projects, such as those mentioned above, must be continued to give further
insights into these healthcare technologies.

Acknowledgments

This work was endorsed by the Genomic Medicine Alliance Health Economics Working Group.

References

Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., Torrance GW, 2015. Methods for the
Economic Evaluation of Health Care Programmes. Oxford University Press.
Fragoulakis, V., Mitropoulou, C., Williams, M.C., Patrinos, G.P., 2015. Economic Evaluation in
Genomics Medicine. Elsevier/Academic Press.
Jowett, S., Bryan, S., Mahé, I., Brieger, D., Carlsson, J., Kartman, B., et al., 2008. A multinational
investigation of time and traveling costs in attending anticoagulation clinics. Value Health 11,
207–212.
Meckley, L.M., Gudgeon, J.M., Anderson, J.L., Williams, M.S., Veenstra, D.L., 2010. A policy model
to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeco-
nomics 28, 61–74.
Mitropoulou, C., Fragoulakis, V., Bozina, N., Vozikis, A., Supe, S., Bozina, T., et al., 2015. Economic
evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrilla-
tion patients with ischemic stroke. Pharmacogenomics 16, 137–148.
Mizzi, C., Dalabira, E., Kumuthini, J., Dzimiri, N., Balogh, I., Bas¸ak, N., et al., 2016. A European
spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics.
PLoS One 11, e0162866.
Nahvijou, A., Daroudi, R., Tahmasebi, M., Hashemi, F.A., Hemami, M.R., Sari, A.A., et al., 2016.
Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a mid-
dle-income country with a low incidence rate of cervical cancer. PLoS One 11, e0156705.
O’Brien, C.L., Gage, B.F., 2005. Costs and effectiveness of ximelagatran for stroke prophylaxis in
chronic atrial fibrillation. JAMA 293, 699–706.
Olgiati, P., Bajo, E., Bigelli, M., De Ronchi, D., Serretti, A., 2012. Should pharmacogenetics be in-
corporated in major depression treatment? Economic evaluation in high-and middle-income
European countries. Prog. Neuropsychopharmacol Biol. Psychiatry 36, 147–154.
Park, D.J., Kang, J.H., Lee, J.W., Lee, K.E., Wen, L., Kim, T.J., et al., 2015. Cost-effectiveness analysis
of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in
Korea. Arthritis Care Res. 67, 280–287.
Pink, J., Pirmohamed, M., Lane, S., Hughes, D., 2014. Cost-effectiveness of pharmacogenetics-
guided Warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin. Pharmacol.
Ther. 95, 199–207.